145 results
8-K
ADAP
Adaptimmune Therapeutics Plc
30 May 24
Entry into a Material Definitive Agreement
4:09pm
-cel and used in the SURPASS clinical trials). Galapagos and Adaptimmune will conduct a proof of concept (Phase 1) trial to evaluate the safety
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
30 May 24
Entry into a Material Definitive Agreement
4:09pm
trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing … Poster presentation ESMO 2021: Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
Park, UK.
Data presentation
Poster presented by George Pope, Ph.D., Associate Director Preclinical Safety at Adaptimmune, entitled "Development
8-K
EX-99.1
v8op545td r3761u
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
ovg5ltj tp4ojr84
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
EX-99.1
hj2qn
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
EX-10.1
ov945
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
1gvy7
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
y6c 1xllaxm28qyzdv
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
o2fid8dj8 8o9imz
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
sw5f058
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am